Search results
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via AOL· 20 hours agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a...
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1 (NYSE:ABBV)
Seeking Alpha· 19 hours agoAbbVie (ABBV) is set to report Q1 earnings results on April 26th. Analysts expect a profit of $2.26...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 15 hours agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie (ABBV) to Release Quarterly Earnings on Friday
ETF DAILY NEWS· 1 day agoAbbVie (NYSE:ABBV – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, April 26th. Analysts expect the company to announce ...
AbbVie announces LEVEL UP results in atopic dermatitis study By Investing.com
Investing.com· 20 hours agoThe study focused on adult and adolescent patients who had an inadequate response to systemic...
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Reuters· 12 hours agoCigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 20 hours agoChicago, IL – April 25, 2024 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk...
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 4 days agoAbbVie ABBV will report first-quarter 2024 results on Apr 26, before market open. In the last...
REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study
Reuters via Yahoo Finance· 21 hours ago(Corrects to remove extraneous text and to add Regeneron ticker symbol) April 25 (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory ...
AbbVie Inc. (NYSE:ABBV) to Post Q1 2024 Earnings of $2.21 Per Share, William Blair Forecasts
ETF DAILY NEWS· 6 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Research analysts at William Blair issued their Q1 2024 EPS estimates for AbbVie in a research note issued to investors ...